Literature DB >> 26553417

Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?

Palak J Trivedi1, Gideon M Hirschfield1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26553417     DOI： 10.1038/nrgastro.2015.187

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

Authors:  Ulrich Beuers; M Eric Gershwin; Robert G Gish; Pietro Invernizzi; David E J Jones; Keith Lindor; Xiong Ma; Ian R Mackay; Albert Parés; Atsushi Tanaka; John M Vierling; Raoul Poupon
Journal:  Hepatology       Date:  2015-09-15       Impact factor: 17.425

2.  Liver disease in the UK.

Authors:  Gideon M Hirschfield; Collette Thain; Martine Walmsley; Ann Brownlee; David E Jones
Journal:  Lancet       Date:  2015-02-07       Impact factor: 79.321

3.  Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis.

Authors:  Christophe Corpechot; Farid Gaouar; Yves Chrétien; Catherine Johanet; Olivier Chazouillères; Raoul Poupon
Journal:  J Hepatol       Date:  2011-05-19       Impact factor: 25.083

4.  The presentation and diagnosis of 100 patients with primary biliary cirrhosis.

Authors:  S Sherlock; P J Scheuer
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

5.  Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.

Authors:  C Degott; E S Zafrani; P Callard; B Balkau; R E Poupon; R Poupon
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

6.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

Authors:  Marco Carbone; George F Mells; Greta Pells; Muhammad F Dawwas; Julia L Newton; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones
Journal:  Gastroenterology       Date:  2012-12-12       Impact factor: 22.682

7.  Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.

Authors:  Palak J Trivedi; Tony Bruns; Angela Cheung; Ka-Kit Li; Clemens Kittler; Teru Kumagi; Husnain Shah; Christopher Corbett; Nadya Al-Harthy; Unsal Acarsu; Catalina Coltescu; Dhiraj Tripathi; Andreas Stallmach; James Neuberger; Harry L A Janssen; Gideon M Hirschfield
Journal:  J Hepatol       Date:  2014-02-15       Impact factor: 25.083

8.  Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Authors:  Willem J Lammers; Gideon M Hirschfield; Christophe Corpechot; Frederik Nevens; Keith D Lindor; Harry L A Janssen; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; Pietro Invernizzi; Pier M Battezzati; Albert Parés; Andrew K Burroughs; Andrew L Mason; Kris V Kowdley; Teru Kumagi; Maren H Harms; Palak J Trivedi; Raoul Poupon; Angela Cheung; Ana Lleo; Llorenç Caballeria; Bettina E Hansen; Henk R van Buuren
Journal:  Gastroenterology       Date:  2015-08-07       Impact factor: 22.682

9.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

Review 10.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425
  10 in total
  5 in total

1.  Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?

Authors:  Matthew J Coleshill; Eindra Aung; Jane E Carland; Kate Faasse; Sophie Stocker; Richard O Day
Journal:  Ther Innov Regul Sci       Date:  2020-07-13       Impact factor: 1.778

2.  Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Authors:  Maren H Harms; Willem J Lammers; Douglas Thorburn; Christophe Corpechot; Pietro Invernizzi; Harry L A Janssen; Pier M Battezzati; Frederik Nevens; Keith D Lindor; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; George N Dalekos; Tony Bruns; Albert Parés; Andrew L Mason; Xavier Verhelst; Kris V Kowdley; Jorn C Goet; Gideon M Hirschfield; Bettina E Hansen; Henk R van Buuren
Journal:  Am J Gastroenterol       Date:  2017-12-12       Impact factor: 10.864

3.  S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.

Authors:  Xi-Hua Dong; Di Dai; Zhi-Dong Yang; Xiao-Ou Yu; Hua Li; Hui Kang
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

4.  Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.

Authors:  Lina Feng; Kaihui Dong; Xiaoxue Zhang; Bo Ma; Lin Chen; Qianqian Yang; Qingling Chen; Xiaoyu Wen; Qinglong Jin
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

5.  Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.

Authors:  Lukas Burghart; Emina Halilbasic; Philipp Schwabl; Benedikt Simbrunner; Albert Friedrich Stättermayer; Oleksandr Petrenko; Bernhard Scheiner; David Bauer; Matthias Pinter; Kaan Boztug; Mattias Mandorfer; Michael Trauner; Thomas Reiberger
Journal:  J Gastroenterol       Date:  2021-12-11       Impact factor: 7.527
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.